Although oligodendrogliomas are associated with CIC mutations (up to 70%) [46, 47], astrocytomas frequently harbor TP53 and ATRX mutations [48] and confirmation of 1p/19q co-deletion is needed to distinguish both tumors according to the 2021 WHO classification. This evidence concerns the gene ATRX and astrocytoma (excluding glioblastoma).